Peer-reviewed veterinary case report
Echocardiogram measures for dogs with pulmonary valve stenosis
By Nishimura, Satoko et al.·Published in Journal of veterinary internal medicine·2018·Department of Medicine and Epidemiology, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Echocardiographic evaluation of velocity ratio, velocity time integral ratio, and pulmonary valve area in dogs with pulmonary valve stenosis.
- Species:
- dog
Plain-English summary
A group of 27 dogs with pulmonary valve stenosis (PS), a condition that can cause serious heart problems, were evaluated to see how different treatments affected their heart function. After receiving the medication atenolol, the dogs showed a significant decrease in blood pressure measurements related to their heart condition, indicating some improvement. However, other assessment methods that are less affected by blood flow did not show any significant changes. This suggests that while atenolol can help lower certain pressures in the heart, it doesn't change all the ways we measure the severity of PS.
People also search for: dog pulmonary valve stenosis treatment · atenolol for dogs heart problems · dog heart medication effects
Abstract
BACKGROUND: Velocity ratio, velocity time integral (VTI) ratio, and pulmonary valve area indexed to body surface area (iPVA) are methods of assessment of pulmonary valve stenosis (PS) severity that are less dependent on blood flow. Studies evaluating these methods are limited. OBJECTIVES: To determine the effects of butorphanol, atenolol, and balloon valvuloplasty (BV) on velocity ratio, VTI ratio, iPVA, mean PG, and max PG. ANIMALS: Twenty-seven dogs with PS (max PG >50 mm Hg). METHODS: Prospective study. All dogs underwent an echocardiogram at baseline, 5-minutes after administration of butorphanol (0.2-0.25 mg/kg IV), and 2-to-4 weeks after atenolol (1-1.5 mg/kg q12h). Twenty-one of these were evaluated 24-hours after BV. RESULTS: There were no significant differences (P > .05) amongst any of the methods of assessment of PS severity after butorphanol. After atenolol, mean (SD) of mean (57.0 [21.0] mm Hg) and max PG (93.1 [33.8] mm Hg) were significantly decreased (P ≤ .047) compared with baseline (65.2 [26.2] mm Hg and 108 [44.4] mm Hg, respectively). After atenolol, there were no significant (P ≥ .12) differences in velocity ratio (0.29 [0.09]), VTI ratio (0.18 [0.05]), or iPVA (0.43 [0.16] cm/m) compared with baseline (0.30 [0.09], 0.19 [0.09], 0.44 [0.17] cm/m, respectively). CONCLUSIONS AND CLINICAL IMPORTANCE: Atenolol might reduce mean and max PG but does not alter less flow-dependent methods of assessment of PS severity (velocity ratio, VTI ratio, and iPVA) in dogs with PS. Results support an integrative approach to assessment of PS severity that includes less flow-dependent methods, particularly in states of altered flow or right ventricular function.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30079482/